Whitehawk Therapeutics Q1 net loss $22.2M; cash $123M funds into 2028

Whitehawk Therapeutics, Inc.

2026-Q1 EPS reported -$0.32 vs consensus -$0.36 ▲ beat (+12.1%)

Net loss of $22.2M for Q1 2026 vs net income of $73.0M in Q1 2025, which included an $87.4M gain on sale of Aadi Subsidiary.
Cash, cash equivalents and short-term investments of $123.0M as of March 31, 2026, down from $145.7M at Dec 31, 2025; expected to fund operations into 2028.
R&D expenses of $17.2M, including $5.3M development milestone to WuXi Biologics, up from $8.8M in Q1 2025.
Phase 1 trials for HWK-007 and HWK-016 continue enrollment; IND for HWK-206 in small-cell lung cancer/neuroendocrine tumors on track for mid-2026.
Initial Phase 1 data for pipeline candidates expected in the first half of 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Whitehawk Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026, was $22.2 million.

Period: the quarter ended March 31, 2026
Net income: Net loss for the three months ended March 31, 2026, was $22.2 million
Result: reported results

Exact text from the filing

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

View on SEC.gov

Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.